White matter hyperintensity topography in Alzheimer's disease and links to cognition. 2022

Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders,", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.

White matter hyperintensities (WMH) are often described in Alzheimer's disease (AD), but their topography and specific relationships with cognition remain unclear. Regional WMH were estimated in 54 cognitively impaired amyloid beta-positive AD (Aβpos-AD), compared to 40 cognitively unimpaired amyloid beta-negative older controls (Aβneg-controls) matched for vascular risk factors. The cross-sectional association between regional WMH volume and cognition was assessed within each group, controlling for cerebral amyloid burden, global cortical atrophy, and hippocampal atrophy. WMH volume was larger in Aβpos-AD compared to Aβneg-controls in all regions, with the greatest changes in the splenium of the corpus callosum (S-CC). In Aβpos-AD patients, larger total and regional WMH volume, especially in the S-CC, was strongly associated with decreased cognition. WMH specifically contribute to lower cognition in AD, independently from amyloid deposition and atrophy. This study emphasizes the clinical relevance of WMH in AD, especially posterior WMH, and most notably S-CC WMH.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001284 Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. Atrophies
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D066127 White Matter The region of CENTRAL NERVOUS SYSTEM that appears lighter in color than the other type, GRAY MATTER. It mainly consists of MYELINATED NERVE FIBERS and contains few neuronal cell bodies or DENDRITES. Cerebellar White Matter,Cerebellar White Matters,Matter, Cerebellar White,Matter, White,Matters, Cerebellar White,Matters, White,White Matter, Cerebellar,White Matters,White Matters, Cerebellar

Related Publications

Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
December 2023, BMC psychiatry,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
April 2024, Alzheimer's research & therapy,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
October 2012, AJNR. American journal of neuroradiology,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
December 2023, Neurobiology of aging,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
January 2013, European neurology,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
March 1996, Journal of neurology,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
January 2006, Dementia and geriatric cognitive disorders,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
July 2011, Stroke,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
February 2023, GeroScience,
Antoine Garnier-Crussard, and Salma Bougacha, and Miranka Wirth, and Sophie Dautricourt, and Siya Sherif, and Brigitte Landeau, and Julie Gonneaud, and Robin De Flores, and Vincent de la Sayette, and Denis Vivien, and Pierre Krolak-Salmon, and Gaël Chételat
January 2021, The journal of prevention of Alzheimer's disease,
Copied contents to your clipboard!